About
Proterris develops carbon monoxide-based therapies to prevent organ transplant complications and treat inflammatory diseases and oncology by leveraging the cytoprotective, anti-inflammatory, and anti-fibrotic properties of carbon monoxide.
Explore Proterris's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.